590 related articles for article (PubMed ID: 18854571)
1. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE).
Grothey A; Sugrue MM; Purdie DM; Dong W; Sargent D; Hedrick E; Kozloff M
J Clin Oncol; 2008 Nov; 26(33):5326-34. PubMed ID: 18854571
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study.
Kozloff M; Yood MU; Berlin J; Flynn PJ; Kabbinavar FF; Purdie DM; Ashby MA; Dong W; Sugrue MM; Grothey A;
Oncologist; 2009 Sep; 14(9):862-70. PubMed ID: 19726453
[TBL] [Abstract][Full Text] [Related]
3. Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study.
Grothey A; Flick ED; Cohn AL; Bekaii-Saab TS; Bendell JC; Kozloff M; Roach N; Mun Y; Fish S; Hurwitz HI
Pharmacoepidemiol Drug Saf; 2014 Jul; 23(7):726-34. PubMed ID: 24830357
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of chemotherapy plus bevacizumab as second-line therapy for patients with metastatic colorectal cancer that progressed on bevacizumab with chemotherapy: the Gunma Clinical Oncology Group (GCOG) trial 001 SILK study.
Tsutsumi S; Ishibashi K; Uchida N; Ojima H; Hosouchi Y; Yashuda N; Kigure W; Yamauchi S; Asao T; Ishida H; Kuwano H
Oncology; 2012; 83(3):151-7. PubMed ID: 22889925
[TBL] [Abstract][Full Text] [Related]
5. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer.
Kabbinavar FF; Hambleton J; Mass RD; Hurwitz HI; Bergsland E; Sarkar S
J Clin Oncol; 2005 Jun; 23(16):3706-12. PubMed ID: 15867200
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab in the treatment of metastatic colorectal cancer (mCRC) in second- and third-line settings.
Giantonio BJ
Semin Oncol; 2006 Oct; 33(5 Suppl 10):S15-8. PubMed ID: 17145520
[TBL] [Abstract][Full Text] [Related]
7. Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab-based treatment in metastatic colorectal cancer.
Guiu B; Petit JM; Bonnetain F; Ladoire S; Guiu S; Cercueil JP; Krausé D; Hillon P; Borg C; Chauffert B; Ghiringhelli F
Gut; 2010 Mar; 59(3):341-7. PubMed ID: 19837679
[TBL] [Abstract][Full Text] [Related]
8. Safety and effectiveness of bevacizumab treatment for metastatic colorectal cancer: final results from the Avastin(®) Registry - Investigation of Effectiveness and Safety (ARIES) observational cohort study.
Hurwitz HI; Bekaii-Saab TS; Bendell JC; Cohn AL; Kozloff M; Roach N; Mun Y; Fish S; Flick ED; Grothey A;
Clin Oncol (R Coll Radiol); 2014 Jun; 26(6):323-32. PubMed ID: 24686090
[TBL] [Abstract][Full Text] [Related]
9. Survival outcomes of bevacizumab beyond progression in metastatic colorectal cancer patients treated in US community oncology.
Cartwright TH; Yim YM; Yu E; Chung H; Halm M; Forsyth M
Clin Colorectal Cancer; 2012 Dec; 11(4):238-46. PubMed ID: 22658457
[TBL] [Abstract][Full Text] [Related]
10. Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer.
Yamamoto S; Nagashima K; Kawakami T; Mitani S; Komoda M; Tsuji Y; Izawa N; Kawakami K; Yamamoto Y; Makiyama A; Yamazaki K; Masuishi T; Esaki T; Nakajima TE; Okuda H; Moriwaki T; Boku N
BMC Cancer; 2021 Oct; 21(1):1159. PubMed ID: 34715820
[TBL] [Abstract][Full Text] [Related]
11. Survival for metastatic colorectal cancer in the bevacizumab era: a population-based analysis.
Renouf DJ; Lim HJ; Speers C; Villa D; Gill S; Blanke CD; O'Reilly SE; Kennecke H
Clin Colorectal Cancer; 2011 Jun; 10(2):97-101. PubMed ID: 21859560
[TBL] [Abstract][Full Text] [Related]
12. Final overall survival results and effect of prolonged (≥ 1 year) first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trial.
Smith I; Pierga JY; Biganzoli L; Cortes-Funes H; Thomssen C; Saracchini S; Nisenbaum B; Pelaez I; Duenne AA; Pritchard KI
Breast Cancer Res Treat; 2011 Nov; 130(1):133-43. PubMed ID: 21830015
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
Shih T; Lindley C
Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999
[TBL] [Abstract][Full Text] [Related]
14. [Efficacy of chemotherapy combined with bevacizumab for metastatic colorectal cancer].
Momoi A; Motomura S; Hashimoto C; Takasaki H; Takemura S; Takagi S; Akaike M
Gan To Kagaku Ryoho; 2011 Jan; 38(1):79-83. PubMed ID: 21368462
[TBL] [Abstract][Full Text] [Related]
15. Circulating endothelial cells predict for response to bevacizumab-based chemotherapy in metastatic colorectal cancer.
Matsusaka S; Suenaga M; Mishima Y; Takagi K; Terui Y; Mizunuma N; Hatake K
Cancer Chemother Pharmacol; 2011 Sep; 68(3):763-8. PubMed ID: 21170650
[TBL] [Abstract][Full Text] [Related]
16. Circulating endothelial progenitors and CXCR4-positive circulating endothelial cells are predictive markers for bevacizumab.
Matsusaka S; Mishima Y; Suenaga M; Terui Y; Kuniyoshi R; Mizunuma N; Hatake K
Cancer; 2011 Sep; 117(17):4026-32. PubMed ID: 21858803
[TBL] [Abstract][Full Text] [Related]
17. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study.
Tebbutt NC; Wilson K; Gebski VJ; Cummins MM; Zannino D; van Hazel GA; Robinson B; Broad A; Ganju V; Ackland SP; Forgeson G; Cunningham D; Saunders MP; Stockler MR; Chua Y; Zalcberg JR; Simes RJ; Price TJ
J Clin Oncol; 2010 Jul; 28(19):3191-8. PubMed ID: 20516443
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan.
Shiroiwa T; Fukuda T; Tsutani K
Clin Ther; 2007 Oct; 29(10):2256-67. PubMed ID: 18042483
[TBL] [Abstract][Full Text] [Related]
19. Healthcare costs associated with bevacizumab and cetuximab in second-line treatment of metastatic colorectal cancer.
Yang H; Yu AP; Wu EQ; Yim YM; Yu E
J Med Econ; 2011; 14(5):542-52. PubMed ID: 21728912
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab in combination with fluoropyrimidine-based chemotherapy for the first-line treatment of metastatic colorectal cancer.
Whyte S; Pandor A; Stevenson M; Rees A
Health Technol Assess; 2010 Oct; 14(Suppl. 2):47-53. PubMed ID: 21047491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]